Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results.
SITC
Society for Immunotherapy of Cancer (SITC)
June 1, 2022
,
El-Khoueiry, et al.
No items found.
Balstilimab (PD-1 inhibitor)
RaPiDS (GOG-3028): A Randomized Phase II Study of Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer.
Other Articles & Publications
SGO 2021 Virtual Annual Meetings on Women's Cancer Abstracts
June 1, 2022
,
O'Malley, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors.
AACR
American Association for Cancer Research (AACR)
June 1, 2022
,
Tanne, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
Fc-enhanced anti-CTLA-4 Antibody, AGEN1181: New Mechanistic Insights for Potent Antitumor Immunity and Combination Potential in Treatment-resistant Solid Tumors.
AACR
American Association for Cancer Research (AACR)
June 1, 2022
,
Tanne, et al.
No items found.